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Chapter 1: Literature Review 
1. Introduction 
 South Africa is currently one of the countries most affected by the Acquired Immunodeficiency 
Syndrome (AIDS) epidemic in the world (UNAIDS, 2013). In 2013, approximately 6.3 million (6 – 6.5 
million) people were living with Human Immunodeficiency Syndrome – type 1 (HIV-1), with over 200 
000 AIDS related deaths occurring annually (UNAIDS, 2013). The subtype-C epidemic is the largest 
worldwide and is also the major circulating HIV-1 subtype in South Africa (Department of Health, 
2014). In 2016, the South African national treatment rollout program increased access to antiretroviral 
treatment for people living with HIV-1, with approximately 3.4 million people (with CD4 count under 
500 cells/µl) receiving highly active antiretroviral therapy (HAART) in the public sector alone 
(UNAIDS, 2016). The South African national treatment program includes 2 nucleoside reverse 
transcriptase inhibitors (NRTIs) {AZT/TDF and 3TC or FTC if there are contradictions to 3TC} and 1 
non-nucleoside reverse transcriptase inhibitors (NNRTI) {EFV or NVP for pregnant women} provided 
as a fixed-dose combination in the first line regimen and 2 NRTIs (AZT/TDF and 3TC or FTC and 1 
PI (LPV/r or ATV/r) in the second line regime (Department of Health, 2014). 
 
However, the gains (including, improved prognosis of HIV-1 infected people and quality of life) due to 
the increased access to HAART risk being eroded by the emergence of drug resistance (Ives et al., 
2001). Drug resistance is attributed to the high replication capacity of HIV-1, with 1010 viral particles 
being produced daily in people living with HIV-1 (Ives et al., 2001, Preston et al., 1988). In addition, 
reverse transcriptase (RT), that helps HIV-1 to replicate, lacks proofreading capabilities resulting in the 
incorporation of the wrong nucleotide at least once per replication cycle (Preston et al., 1988). 
Consequently, this results in large variation in new particles produced (Roberts et al., 1988). In the 
development of drug resistance, antiretroviral drugs (ARVs) apply selective pressure on these naturally 
mutating viruses (Coffin, 1995). In the presence of incomplete viral suppression, variant with a 
competitive advantage are selected and these drug resistant mutants become the dominant strains 
thereafter (Coffin, 1995). Drug resistance is the leading factor for treatment failure. Other factors 
include a low genetic barrier to resistance of certain drugs, poor adherence, and inadequate drug plasma 
concentrations and the presence of pre-existing drug resistant mutants (Coffin, 1995). 
 
Studies have well characterized the development of nucleoside reverse transcriptase inhibitor resistance, 
with AZT/d4T associated thymidine analogue resistance mutations (TAMs) being the most studied. 
There are two TAM pathways which show evidence of appearing in an ordered sequence; namely: 
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TAM-1 (41L, 210W, 215Y) and TAM-2 (67N, 70R, 215F, 219E/Q) (Cozzi-Lepri et al., 2005). TDF is 
one of the newer NRTIs replacing d4T in the South African national treatment plan in 2010 (Department 
of Health, 2014). Subtype B studies have reported a TDF resistance mutation pathway that includes 
K65R and nucleoside analogue mutations: Q151M, A62V, V75I, F77L and F116Y (Miller, 2004, 
Garforth et al., 2014b). However, the interaction between TDF associated mutations and other NRTI 
and NNRTI resistance mutations in subtype C sequences remains unclear.  
 
There have been recent reports of rapid selection of K65R mutation in subtype C viruses in TDF-treated 
patients (Skhosana et al., 2015, Sunpath et al., 2012a). This has important public health implications in 
limited resource countries, such as South Africa, as resistance to the first line regimen might lead to 
switching to a more costly 2nd line regimen. In addition, the drug resistant viruses can be transmitted to 
newly infected individuals and reduce patient’s treatment options when they start treatment. It is 
therefore important to monitor the development of drug resistance and cross-resistance in patients on 




1.1 Human Immunodeficiency Virus 
Human immunodeficiency virus (HIV-1) was discovered in 1983 and is known to be the leading cause 
of Acquired Immunodeficiency Syndrome (AIDS) (Barré-Sinoussi et al., 2013, Mauck and Straten, 
2008). HIV-1 belongs to a group of retroviruses called Retroviridae (Engelman and Cherepanov, 2012b, 
Mauck and Straten, 2008). HIV-1 has a different structure from the other members of the family. It is 
roughly spherical, somewhat pleomorphic and measures around 120nm in diameter. HIV-1 consists of 
two single stranded RNA molecules wrapped in a conical capsid comprising of the p24 viral protein 
(Figure 1.1) (Inhibitors, 2002). 
 
 
Figure 1.1: General features of HIV-1 virion. Adapted from (Freed, 1998). 
 
 
The full HIV-1 genome is encoded on one long strand that contains a RNA genome that encodes 9 
genes (Figure1.2).  Within these nine genes, there are three major genes called gag (group-specific 
antigen), pol (polymerase) and env (envelope glycoprotein) (Freed, 2001)). Gag is a genomic region 
that codes for four structural proteins, which are matrix (p17), capsid ( p24), nucleocapsid ( p7) and p6 
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(Freed, 1998). The matrix is important for the incorporation of viral surface glycoproteins into virion 
and early post entry events (Dorfman et al., 1994, Freed, 1998). The capsid plays a crucial role in virus 
assembly and maturation (Freed, 1998)). The nucleocapsid is required for the encapsidation of the viral 
RNA, membrane binding, pre-integration and transcription (Accola et al., 1998, Freed, 2001). P6 is 
needed for the release of assembled virion from the cell surface (Kondo and Göttlinger, 1996). The Pol 
region codes for 3 enzymes which are protease (p11), reverse transcriptase (p66/p51) and Integrase 
(p32). The Env viral glycoprotein codes for surface GP120 and transmembrane GP41(Frankel and 
Young, 1998). The other six genes are vif, vpr, rev, vpu, tat and nef (Frankel and Young, 1998). Tat 
and rev are two regulatory genes for HIV-1 gene expression. Tat (p16 and p14) consists of 80 to 101 
amino acids which are needed for transcription of the viral genome (Kuiken et al., 2008). Rev (p19) is 
required for export of RNA from the nucleus to the cytoplasm. It consists of 116 amino acids which are 
nuclear localization sequence (NLS) and nuclear export sequence (NES)  (Freed, 2001, Pond et al., 
2009). Vif, vpr,vpu and nef  are not required for  virus replication. However, they provide different 




Figure1.2: HIV-1 full genome with three major genes that codes for different proteins and enzymes. Adapted 






1.2 Classification of HIV-1 Strains 
 HIV-1 is divided into two related lentiviruses, HIV-1 and HIV-2 (Nyamweya et al., 2013). HIV-1 is 
divided into 4 major phylogenic groups: M, N O and P. Group M which is referred to as the main or 
major group, is responsible for the majority of the global HIV-1 epidemic (Kostrikis et al., 1995). Group 
M is also subdivided into 9 subtypes (A, B, C, D, F, G, H, J and K). Furthermore, closely related subtype 
can combine to form  CRFs (circulating recombinant forms) (Hemelaar, 2012). Subtype B is dominant 
in America, Europe and Australia(Buonaguro et al., 2007), whereas subtype C is dominant in South 
Africa, horn of Africa and India (Lole et al., 1999). 
 
1.3 HIV-1 Life Cycle 
During the HIV-1 replication cycle, gp120 binds to a CD4 receptor on the surface of the target cell. 
Upon binding, the gp120 undergoes a conformational change resulting in binding to the co-receptors 
(Melikyan et al., 2000). After binding to receptors, HIV-1 envelope and the  CD4 cell membrane fuses, 
and the virion single-stranded ribonucleic acid (ssRNA) is used as a template to synthesize double-
stranded deoxyribonucleic acid (dsDNA) (Harrich and Hooker, 2002). Integrase then carries the DNA 
into the nuclease and integrates it into the host DNA (Figure 1.3) (Freed, 2001). RNA polymerase 
transcribes the integrated viral DNA into mRNA. After transcription, the mRNA is spliced and exported 
from the nucleus into the cytoplasm. In the cytoplasm, pieces of mRNA are translated into elongated 
chains of viral proteins and enzymes. On the cell surface, the viral RNA assembles with newly 
synthesized proteins and forms an immature virus (Engelman and Cherepanov, 2012a). Viral protease 
then cleaves the poly-proteins within the virion for the production of mature infectious virus particles 






Figure 1.3: Diagrammatic representation of the HIV-1 life cycle. HIV-1 infects the CD4 T cells using gp120 of 
the envelope, the viral RNA is then released inside the host cells. HIV-1 RNA is reverse transcribed into cDNA 
which is then integrated into the host’s DNA. Viral DNA is then synthesised into new viral RNA used to make 
viral proteins followed by protein translation inside the cytoplasm and a new, immature, HIV-1 virus is released 
and infects more cells  (Monini et al., 2004).   
 
 
1.4 HIV-1 Reverse Transcriptase 
 
Reverse transcriptase is a viral enzyme encoded within the pol region of the HIV-1 genome. It mediates 
the conversion of the RNA genome to double-stranded DNA during reverse transcription. This enzyme 
is a heterodimer made up of a p66 and p51 subunit. HIV-1 RT performs multiple enzyme activities: 
RNA-dependent DNA polymerase, DNA-dependent DNA polymerase and RNAse H activities.  The 
p66 subunit consists of 560 amino acid while p51 consists of only 440 amino acids and lacks the 
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Ribonuclease H (RNase H) domain that is formed by the additional 120 residues. However, both 
subunits contain similar subdomains in their polymerase domain which are described with reference to 
a human right hand (Hu and Hughes, 2012) namely the Finger, Thumb, Palm and Connection 
subdomains (Temiz and Bahar, 2002). The p66 polymerase domain has the active site in the palm 
subdomain that contains a catalytic triad in position D110, D185 and D186. P66 plays a catalytic role 










1.5 Antiretroviral Therapy Drug Classes 
Antiretroviral therapy has greatly altered the management of HIV-1 infection globally and has led to 
the reduction of mortality and morbidity rates in many countries that have successfully implemented a 
national ARV rollout programme. There are currently 6 different antiretroviral drug classes used in 
HIV-1 therapy (Shafer, 2012). These include nucleoside/nucleotide reverse transcriptase inhibitors 
(NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), protease inhibitors (PIs), fusion 
inhibitors and inhibitors of co-receptors and integrase inhibitors. The efficacies of these drugs are 
limited by HIV-1 drug resistance, which is usually caused by mutations in protease and RT (Shafer, 
2002). 
 
1.6 The Nucleoside Reverse Transcriptase Inhibitors (NRTIs) mechanism of action 
The NRTIs are used in the first-line regimens of most countries worldwide, these include: Abacavir 
(ABC), Didanosine (ddI), Zalcitabine (ddC), Stavudine (d4T), Zidovudine (AZT), Tenofovir (TDF), 
Emtricitibine (FTC), and Lamivudine (3TC) (AIDSinfo, 2013). NRTIs inhibit HIV-1 replication by 
acting as DNA chain terminators during reverse transcription of the HIV-1 single-stranded RNA 
genome into complimentary DNA (cDNA). NRTIs are first phosphorylated to an active triphosphate 
form of the drug that competes with the cells naturally produced deoxynucleoside triphosphate (dNTP) 
pools (Shafer, 2002). Once incorporated into a growing cDNA strand, it acts as a chain terminator by 
blocking further insertion of another dNTP molecule, as NRTIs lack a 3’ hydroxyl group that is crucial 
for the formation of a phosphodiester bond during cDNA synthesis by the HIV-1 RT enzyme (Das and 
Arnold, 2013). 
 
1.6.1 Molecular mechanisms of NRTI resistance 
Molecular resistance with NRTIs is the result of the accumulation of mutations in HIV-1 pol gene 
(Johnson et al., 2003). These mutations can be classified as discriminatory or primer unblocking 
mutations (Tang and Shafer, 2012). Discriminatory mutations have been shown to decrease the binding 
of the NRTIs to the RT enzyme, allowing the RT enzyme to discriminate against NRTI incorporation 
onto the growing DNA chain during polymerisation (Whitcomb et al., 2003). These mutations are also 
linked to reduced catalytic activity of the HIV-1 RT enzyme while the insertion of dNTPs remains 
unchanged, causing the virus to continue replicating (Whitcomb et al., 2003). The other mechanism 
involve the phosphorolytic activities, whereby after NRTI incorporation into the viral DNA, chain 
terminating NRTI is removed from the 3’- terminus of the primer. However, this may be affected by 
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NRTI mutation that enhance primer unblocking activities e.g. TAMs (M41L, D67N, K70R, L210W, 
T215F/Y and K219Q/E (Marcelin et al., 2006), which promote the hydrolytic removal of NRTIs, 
leaving a free 3'-OH group to continue DNA synthesis. During this process, they also unblock the primer 
stimulating further extension of viral DNA (Whitcomb et al., 2003). 
 
1.7 The Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) mechanism of action 
NNRTIs are non-competitive inhibitors that bind to hydrophobic pocket close to the active site in the 
enzyme. The binding to the less well-conserved site leads to conformational changes that interfere with 
the formation of the binding pocket leading to a reduced RT activity (Shafer, 2002). There are four 
NNRTIs in clinical use: Navarapine (NVP), Efavirenz (EFV), Etravirine (ETR) and Rilpivirine (RPV) 
(AIDSinfo, 2013). A major limitation of NNRTIs is their relatively low genetic barrier, where only a 
single point mutation is required to cause resistance (Tang and Shafer, 2012). High level resistance to 
NNRTIs may results from single mutation (Shafer, 2002). K101E/P, K103N and E138K are present at 
the rim of pocket and rest other NNRTI resistance mutations are present within the NNRTI binding 
pocket (Ren and Stammers, 2008). A previous study suggests that there are broad classes of NNRTI 
resistance mechanisms: loss of an aromatic ring, steric hindrance and alteration of hydrophobic 
interactions (Das and Arnold, 2013). 
 
1.8 South African treatment programme and TDF 
In 2010, the South African national antiretroviral treatment program adopted a policy to phase out the 
more toxic d4T and replace it with TDF as part of the first-line regimen in South Africa (Department 
of Health, 2014). It is a widely prescribed antiretroviral  that blocks  RT activity (Menéndez-Arias, 
2010). It is usually administered in combination with other NRTIs and NNRTIs (Nelson et al., 2007). 
The K65R mutation has been reported to decrease efficacy of TDF by four-fold (Margot et al., 2003) 
 
1.9 Resistance to TDF 
Initially,  low frquency (2.1%) of resistance  was reported in subtype B TDF-treated patients (Margot 
et al., 2003). In vitro studies identified K65R as the only mutation associated with TDF resistance. 
However, this single mutation causes high level TDF resistance (Wensing et al., 2015). Subtype B study 
has reported the  TDF-resistance pathway including association of K65R with S68G, L100I and Y181C 
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(Theys et al., 2009). K65R still remain the main cause of TDF resistance, and is known to be 
preferentially selected in subtype C (Brenner and Coutsinos, 2009a). Studies reported a rapid selection 
of K65R in subtype C TDF-treated patient (Skhosana et al., 2015, Sunpath et al., 2012b). This has 
important public health implications in limited resource countries, such as South Africa, as resistance 
to first line regimens might lead to switching to more costly 2nd line regimens. In addition, the drug 
resistant virus can be transmitted to newly infected individuals and reduce their options when they start 
treatment. It is therefore important to monitor the development of drug resistance and cross-resistance 
in patients on TDF containing regimens to ensure optimal viral suppression and care of HIV-1 infected 
patients. 
 
1.10 K65R mechanism of resistance 
The K65R mutation is the substitution of lysine (K) to arginine (R) amino acids at residue 65 in the 
catalytic site of HIV-1 RT. K6R is one of the discrimination mutations that confers intermediate 
resistance to ABC, ddI, d4T, 3TC and FTC; causes high resistance to TDF and increase susceptibility 
to AZT (Garforth et al., 2014a). The Lysine (K) 65 which forms a part of nucleotide binding protein is 
located between the β3 and β4 sheets that form the flexible loop in the finger region of HIV-1 RT 
structure (Garforth et al., 2014a). For the incoming dNTP or NRTI-TP to be incorporated into a growing 
DNA strand, the finger subdomain of HIV-1 RT-structure folds towards the primer- template and the 
polymerase active site in the palm subdomain. Subsequent to this a salt bridge is formed between codon 
K65 and the γ phosphate. In the presence of K65R the dNTP can still bind, but alters the nucleotide 
binding specificity (Huang et al., 1998, Sarafianos et al., 1999). The mechanism for rapid selection may 
be explained by the nucleotide sequence dissimilarities that exist in the subtype specific template 
(Invernizzi et al., 2009). Subtype C sequences have unique nucleotide polymorphisms in position 64 
(AAA) 65 (AAG) and 66 (AAG) when compared to non-subtype C sequences, including subtype B 
(Invernizzi et al., 2009). In addition, Subtype C have the homopolymeric stretch that starts from codon 
63 and end at codon 65 and followed by a C base (Brenner and Coutsinos, 2009b). During the synthesise 
of dsDNA from ssDNA template, the enzyme approaches the homopolymeric end at codon 65 and this 
leads to misalignment and slippage. Therefore, the tamplate folds onto itself,  covering the final  T and 
exposing C at codon 65. The incoming nucleotide provides the stability of the misaligned template  
through  hydrogen bond, resulting in correct binding of G to C on the misaligned template. Thereafter, 
the primer and the template strands are re-aligned and this leads to the binding of G to T and the re-
exposed of  C on the aligned template and a second G being incorporated to bind with C base. Finally, 




Figure 1.5: Increased selection of K65R in subtype C. The selection of K65R is initiated by the poly-adenine 
stretches at position   63 and 65. The stop occur in poly stretches in position 65 (Brenner and Coutsinos, 2009b). 
 
1.10.1 K65R mutation in subtype C patients 
In-vitro studies have shown an increased risk in developing the K65R mutation in subtype C infections 
compared to subtype B (Brenner and Coutsinos, 2009a). Data regarding the prevalence of the K65R 
mutation in TDF exposed patients are mixed, with two studies (Skhosana et al., 2015, Sunpath et al., 
2012a) showing a prevalence of more than 65% while two studies (Van Zyl et al., 2013a, Hoffmann et 
al., 2013b) show K65R prevalence of 46% and 23% respectively. Furthermore, it has been found that 
the K65R mutation leads to cross-resistance to the majority of NRTIs {including abacavir (ABC), 
emtricitabine (FTC), lamivudine (3TC), stavudine (d4T)} (Johnson et al., 2011). This could lead to 
more failures to the first line regimen in South Africa, since K65R causes resistance to TDF, leaving 2 
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drugs active (3TC/FTC and EFV ). Since the emergence of K65R has been reported in patients receiving 
EFV or NVP (von Wyl et al., 2008), this implies that all active drugs in the first line regimen will 
eventually  fail. 
 
1.10.2 Antagonistic relationship between K65R and other NRTI-resistance mutation 
Specific combinations of NRTIs cause HIV-1 to evolve  in a pathway of resistance mediated either by 
TAMs or K65R but not both (White et al., 2006b). The mechanism by which TAMs (41L, 67N, 70R, 
210W, 215Y/F, 219E/Q) confer resistance is by facilitating the entry and binding of either 
pyrophosphate (PPi) or adenosine triphosphate (ATP) to the NRTI that has been incorporated at the 3’ 
end of the terminated DNA chain (Arion et al., 1998, Boyer et al., 2001, Meyer et al., 1998). The 
triphosphate intermediate allows the inhibitor to be excised from the DNA chain (Arion et al., 1998, 
Bishop et al., 2008, Meyer et al., 1998), thereby allowing DNA synthesis to resume. The ability of 
TAMs to efficiently excise NRTIs can become increasingly impaired with the accumulation of other 
mutations (Clavel and Hance, 2004), such as the discriminatory M184V mutation (Gu et al., 1995). 
M184V decreases the binding of 3TC and FTC to the RT enzyme by interacting with the oxathiolane 
ring, and therefore increases sensitivity to AZT by reducing the removal of the chain-terminating 
nucleoside (Huang et al., 1998). This can be explained by the fitness constraints imposed by M184V 
which diminishes the ability of RT to effectively remove the drug (Gu et al., 1995). Therefore M184V 
has an antagonistic effect on TAMS, Similarly, K65R and TAMs are also mutually antagonistic and 
rarely seen in the same viral genome (Gu et al., 1995).  
K65R further increase drug resistance to ddI, ABC, TDF, 3TC by a discrimination mechanism (Boyer 
et al., 1994, Deval et al., 2004). This mutation is able to disrupt the hydrogen bonding that involves the 
3’-OH of the incoming deoxynucleotide (dNTP) (Boyer et al., 1994, Deval et al., 2004). It favours the 
direct contact of the natural dNTPs and indirectly negatively influences the binding of NRTI analogue 
by repositioning the template/primer binding site (Boyer et al., 1994, Deval et al., 2004). 
 
1.10.3 Effect of K65R and other mutations 
As already stated, K65R and M184V increases discrimination between the natural nucleotide and the 
NRTIs and impairs its incorporation (Deval et al., 2004). While K65R disrupts the interaction with the 
γ phosphate of the incoming nucleotide, M184V interacts with the oxathiolane ring, allowing the 
discrimination between the incoming dNTPs and the NRTI triphosphates (Huang et al., 1998). M184V 
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is selected in the presence of 3TC and FTC. K65R and M184V single mutants are known to have 
intermediate resistance to ddC, ddI, ABC, 3TC; but the combination of both K65R and M184V is 
reported to increase resistance to these drugs. In contrast, when M184V occurs on the same genome as 
K65R, their combination may have a synergistic resistance effect on 3TC (Gu et al., 1995).  Also, this 
combination was reported to retain susceptibility to TDF (Das et al., 2009, Deval et al., 2004, Parikh et 
al., 2006). The presence of M184V together with K65R increases the binding of the natural substrate, 
i.e. the dNTP, compared to the inhibitor (White et al., 2002). 
Y115F is selected in patients taking ABC (Miller et al., 2000). However, this mutation has also been 
reported to be selected together with K65R in patients taking TDF and never exposed to ABC (Skhosana 
et al., 2015). The combination of these two mutations had previously been found to cause resistance to 
TDF (Stone et al., 2004).  
 
1.11 Computational methods of HIV-1 drug resistance 
Recently, various computational methods have become an important part of drug resistance 
surveillance, and can offer detailed information about the interaction of mutations (Kirchmair et al., 
2011). The Bayesian method uses the data to refine prior knowledge into posterior knowledge which is 
expressed as a probability distribution of models (Deforche et al., 2006). Also various modelling 
methods such as 3D homology modelling, molecular docking and molecular dynamics, are used to 
understand the implications of drug resistance in RT (Das et al., 2009, Huang et al., 1998). 
 
1.11.1 Bayesian Network 
A Bayesian Network (BN) is a probabilistic model represented by direct acyclic graphs that describes 
statistical correlation between multiple variables (Pearl, 1998). A BN is learned from data by searching 
for the most credible network structure that explains casual and cause-effective relationships from data 
using a minimum number of arcs (direct connections between variables), and eventually produces an 
acyclic causality graph (Deforche et al., 2006). BNs can also be learned from the observation of 
variables (nodes), by searching for the network with the maximum number of correlations in the data 
using a minimum number of arcs (Heckerman et al., 1999). The acyclic structures of a BN are also 
capable of representing relationships between the variables through direct conditional or unconditional  
dependencies (Figure 1.6) (Myllymäki et al., 2002). Dependencies are represented by the presence of 
an arc from one variable to another, showing dependencies between all variables in the data (Myllymäki 
et al., 2002). Conditional dependency is represented by the lack of an arc, while unconditional 
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dependency is represented by the arc (Deforche et al., 2006) For example, if a dependency model has 
four variables A, B, C and D, it could be analyzed as follows (Myllymäki et al., 2002): 
 
 
Figure 1.6: A Bayesian Network representing conditional and unconditional dependencies(Myllymäki et al., 
2002). 
 
  “A and B are conditionally dependent on each other, whether values of C and D are known”.   
 “A and C are unconditionally dependent on each other even whether values of both B and D 
are known or not”, 
 “B and C are unconditionally dependent on each other even whether values of both A and D 
are known or not”, 
 “C and D are unconditionally dependent on each other even whether values of A and B are 
known or not”. 
 
After the most credible BN network structure has been found, assessments of the network robustness 
are searched using bootstrapping (Deforche et al., 2008). One-hundred replicates of non-parametric 
bootstraps are performed to derive network robustness by the presence or absence of a particular arc 
(Deforche et al., 2006). According to (Myllymäki et al., 2002, Pearl, 1998), the existence and thickness 
of arcs showing a direct influence amongst the corresponding variables are relative to bootstrap values 
and their importance are coloured according to the arc weight. For example in Figure 1.7, the black arc 
indicates direct influence between resistance mutations, while association between background 
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polymorphisms is shown in green arcs and the blue arcs indicate an influence from background 
polymorphisms on drug resistance associated mutations. Combination between the NNRTI and NRTI 
associated mutations are shown in grey and purple arcs, which show a direct dependency between 
treatments reflecting preference in treatment combinations. Dotted arcs represent a bootstrap of 35% or 
more and solid arcs represent bootstraps over 65% (Deforche et al., 2006). The quality of the candidate 
BN may be assessed using the posterior Bayesian probability score of the network, that is often used 
for model selection; log p(D,𝑆ℎ)= log p(𝑆ℎ) + log p (D\𝑆ℎShSh). The parameters are defined as D= a 
data set of cases; 𝑆ℎ= the hypothesis corresponding to network structure S and  p= 
probability(Heckerman et al., 1995).   
BNs have been successfully used to investigate the interactions of mutations that confer resistance to 
NRTIs and NNRTIs (Deforche et al., 2008, Theys et al., 2009). BNs were also used to gain insight into 
the pathway to nelfinavir resistance, by identifying the role of mutations selected during treatment 




Figure 1.7: Annotated nelfinavir experience Bayesian network expressing direct association between nelfinavir-







1.11.2 3D Homology Modelling using SWISS-MODEL 
Homology modelling is a computational technique, used to determine the three dimensional (3D) 
structure of proteins. High resolution protein structures that are available in public databases are used 
to construct a model of a protein of similar, but unknown structure (Tastan Bishop et al., 2008). This 
provides an understanding of the biological behaviour and biochemical function of uncharacterised 
sequences, brought about by the recognition of homology between protein sequences and known 
structures (Shi et al., 2001). SWISS-MODEL is a widely used automated homology technique for 
protein modelling. It is designed to work with only the amino acid sequence of the submitted target 
protein and uses a known characterized protein structure found in the Protein Data Bank (PDB) as the 
template (Schwede et al., 2003).  
Homology modelling can be divided into four steps, as shown in Figure 1.8: (1) Template selection: 
identification of the correct templates from the PDB, which are necessarily similar to the target sequence 
to be modelled. (2) Alignment: creating an alignment of the target sequence with the template structures; 
(3) Model building;construction of the 3D structure using specific modelling software, eg modeller v9. 
Templates are weighted by their similarity with the target sequences, and (4) Evaluation:evaluate the 
model (Tastan Bishop et al., 2008).  
 
1.11.3 Viewing Structures 
UCSF CHIMERA is used for visualization of the structural modelling results (Pettersen et al., 2004). 
CHEMLAB molecular viewer (Lanaro, 2002) or PyMOL molecular graphics system 2002 (DeLano, 




Figure 1.8:  Illustration of the homology modelling. The steps involve the alignment of homologous sequences 
and adjustment of the alignment using known motifs and conserved features from secondary structure information. 






1.12 Project Aims and objectives 
Aim 
a) To investigate mutational pathways to Tenofovir resistance using a Bayesian Network.  
 
Objectives 
a) To  download subtype B and C sequences from treatment-naïve, TDF exposed and tenofovir-
naïve isolates(d4T) 
b) To determine the frequency of Tenofovir resistance mutations in both subtype B and C 
sequences in naïve vs treated patients.  
c) To investigate the interaction of K65R mutation and other NRTI and NNRTI mutations in TDF 
resistance in subtype B and C using Bayesian Network model. 
d) To demonstrate the interaction of K65R and other mutations using 3D homology modelling 
 
Hypothesis 














Chapter 2: Prevalence of Tenofovir Resistance Mutations in both Subtype B and C 
Sequences. 
2.1 Introduction 
In 2012, the South African national treatment rollout program increased access to antiretroviral 
treatment for people living with HIV-1 infected, with more than 2,6 million people  receiving highly 
active antiretroviral therapy (HAART) in the public sector alone (UNAIDS, 2013, Department of 
Health, 2014). South African national treatment guidelines includes a first-line regimen of 2 NRTIs and 
1 non-nucleoside reverse transcriptase inhibitors (NNRTIs) and a second-line regimen of 2 NRTIs and 
1 protease inhibitors (Department of Health, 2014).  
 
Tenofovir is a widely-prescribed antiretroviral drug and a preferred component of first-line regimens 
during antiretroviral therapy world-wide (Menéndez-Arias, 2010). However, the efficacy of this drug 
is limited by the emergence of the K65R mutation (Department of Health, 2014, Sunpath et al., 2012). 
Several subtype C studies showed high rates of K65R selection in TDF exposed patients, with two 
studies showing a prevalence of more than 65% (Skhosana et al., 2015, Sunpath et al., 2012a) while 
two studies showed a prevalence of 46% and 23% respectively (Van Zyl et al., 2013a, Hoffmann et al., 
2013b). K65R was significantly associated with A62V and S68G mutations, which in combination 
increased viral fitness (Svarovskaia et al., 2008). A previous subtype B study reported a TDF mutation 
pattern that included the TAMs (M41L and L210W) in patients who were previously exposed to AZT 
and d4T (Antinori et al., 2006). Furthermore, Eteibag reported 12% of  TDF patients with the K65R 
that developed TAMs (Etiebet et al., 2013).Since TDF was introduced in South Africa in 2010, 
increasing reports of drug resistance make it necessary to monitor the TDF resistance patterns that 
develop under this drug, especially with it’s prophylactic use as a microbicide gel (Karim et al., 2010). 
 
The aim of this chapter was to determine the frequency of TDF-associated mutations in sequences from 
TDF exposed versus TDF-naïve isolates. In addition, the frequency of TDF-associated mutations found 







2.2.1 Study design 
This was a retrospective, descriptive study. All subtype B and C naïve sequences were downloaded 
from the Los Alamos HIV-1 database (http://www.HIV-1.lanl.gov),while subtype B and C treated 
isolates were downloaded from the Stanford HIV-1 database (http://HIV-1db.stanford.edu/), Briefly, 
the Genotype-Rx application was used to search for any subtype C (or B) isolate from a patient receiving 
TDF. Similarly, those receiving d4T were queried and downloaded. Treatment history was also 
included. Duplicate sequences were removed using Elimdupes available at (http:// www.HIV-
1.lanl.gov).  
2.2.2 Sequence analysis 
Multiple sequence alignments were generated using the ClustalX program (http://www.clustal.org/) 
(Larkin et al., 2007) and manually edited using BIOEDIT (Ibis Biosciences, An Abbott Company, CA. 
USA). Sequences were also analysed using the RegaDB sequence analysis tools to identify the drug 
resistance and natural occurring mutations in the RT region (https://rega.kuleuven.be/cev/regadb). 
 
2.2.3 Statistical analysis 
All statistics was performed using GraphPad Prism® 5 software (Graphpad© Software, Inc) and IBM 
SPSS Statistics 21(SPSS inc., Chicago, Illinois,USA). Chi-square analysis (Fisher’s exact test) with a 
two tailed p-value was performed using Graphpad Prism® 5 to calculate and compare the frequency of 
mutations in subtype B and C viruses from: (1) TDF-treated patients vs naïve patients; (2) d4T-treated 
vs naïve patients. Spearman’s rank correlation (nonparametric correlation) in SPSS was used to explore 
the association between K65R and other NRTI and NNRTI mutations occurring in the presence of TDF. 






A total of 4313 subtype C isolates were downloaded. These included 618 isolates from TDF-treated 
patients (irrespective of prior treatment with d4T), 2597 d4T experienced and 1098 naïve sequences. 
After removing those that were previously treated with d4T, 475 TDF only treated patients were 
analysed. In addition, 2585 TDF-treated, 4030 d4T experienced and 1630 treatment naïve subtype B 
sequences were downloaded and analysed. Duplicates were removed in both TDF and d4T treated 













Figure 2.1: Number of downloaded sequences from both subtype B and C 
 
2.3.1 Subtype C TDF-treated vs naïve 
 Initially, the frequency of mutations in sequences from any patient treated with TDF (irrespective of 
prior treatment with d4T) was compared to sequences from treatment naïve patients (as shown in Figure 
2.2). Significant increases in frequency (p-value <0.05) are indicated in bold. Interestingly, six of these 
mutations (E36A, E44D, S48T, A158S, K166R and L214F) showed a significant decrease in frequency 
(p-value <0.05).  TAMs were detected in the treated isolates, which may be because some sequences 
were from patients who took d4T prior to TDF. The most frequent drug resistance mutations were 
M184V (47%), followed by K65R (24%) and two NNRTIs: K103NRS (35%) and V106M (30%), 
respectively. 
 
Sequences downloaded from Stanford and Los Alamos HIV-1 database (n=13820) 
Subtype C Sequences (n=4313) 
Treatment-




















































































































































































Figure 2.2: Significant prevalence of subtype C TDF-treated vs subtype C naïve 
 
 
TDF-treated sequences were then grouped according to their treatment history: 1) TDF-treated without 
a history of d4T treatment (Figure 2.2A); 2) d4T-treated prior to TDF (Figure 2.2B). This was to 
determine whether the presence of TAMs prevented the emergence of K65R in patients switched to 
TDF. While the frequency of K65R was higher (31%) in those treated with TDF only, K65R was still 
prevalent (17%) in those switched from d4T to TDF. K46Q was found only in the TDF-treated group 
in 2% (8/475) of sequences and all sequences that developed K46Q also developed K65R. As expected, 
the frequency of TAMs were much higher in the d4T treated group compared to the TDF group, as d4T 
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2.3.2 Subtype C TDF vs d4T isolates 
Sequences from d4T treated patients (without exposure to TDF) were also analysed to determine 
whether K65R is selected for by d4T. K65R was found in 5% of d4T-treated and 31% of TDF-treated 
sequences. S68N was higher in TDF (5%) than in d4T-treated (0.4%) sequences. A62V was also higher 
in TDF (9%) versus d4T-treated (4%) sequences. K70E which has been previously reported to be 
selected by TDF was 4% in TDF-treated and 1% in d4T-treated sequences. Y115F was found in 8% of 
TDF-treated, while in d4T was 1%. M184V, which is associated with 3TC resistance, had a higher 
frequency (64%) in d4T-treated compared to 46% in TDF-treated. Conversely, M184I was higher in 
TDF-treated (7%) compared to d4T-treated (2%), although the overall frequency was lower than 
M184V. As expected, TAMs had a higher frequency in d4T-treated sequences: D67N (17%), T215F/Y 
(14%), K70R (12%) and M41L (8%) versus D67N (11%), T215F/Y (8%), K70R (6%) and M41L(4%). 
Four NNRTI mutations (V106M (33%), Y181C (21%), G190A (19%) and V179D (17%) respectively) 
were higher in TDF-treated, while 2 NNRTI mutations (K103NS (44%) and K101E/Q (15%) were 
higher in d4T-treated.  
 
 










































































































2.3.3 Subtype B TDF treated vs treated-naïve 
The frequency of mutations in Subtype B viruses from patients treated with TDF were also investigated. 
4215 subtype B sequences were downloaded. Of these 2585 were from TDF-treated, and 1630 from 
drug-naïve isolates; these were downloaded from the Stanford and Los Alamos HIV-1 databases 
respectively. Significantly different mutations are shown in the graph below (Figure 2.4). Most 
mutations showed a significant increased after TDF-treated. However, five mutations significantly 
decreased (K11R/T, E169D, K173E/N/R, Q207E/K and R211Q/R) (Figure: 13). K65R frequency was 
10%, while Y115F was 9%. Interestingly, the frequency of TAMs also showed a significant increased 
(M41L (28%), K70R (15%), L210W (20%), T215F/Y (38%), K219Q/E (22%). Frequency of M184I 
and M184V was 4% and 38% respectively. Ten NNRTI mutations showed significantly increased 
frequencies: K103N (30%), A98G (16%), G190A/S (14%), K101E (13%), V179D (13%), V108I (7%), 























































































































































































2.3.4 Subtype B vs subtype C TDF-treated isolate 
The mutations significantly associated with TDF treatment for both subtypes were plotted on a graph 
(Figure 2.5) to show the differences between the two subtypes. Of note, was the frequency of K65R in 
subtype C (31%) versus subtype B (10%). S68G which was previously reported to associate with K65R 
was higher in subtype B (7%) compared to subtype C (5%), while S68N was higher in subtype C (5%) 
versus subtype B (1%). Y115F which is known to be associated with K65R was higher in subtype C 
(8%) compared to B (2%). K70E which is selected by TDF was also higher in subtype C (4%) versus 
subtype B (1%). A62V was higher in subtype C (9%) compared to subtype B (4%).  The frequency of 






































































































































































































2.3.5 K65R correlation with other NRTIs and NNRTIs 
From those that received TDF irrespective of whether they were switched from d4T, K65R positively 
correlated (p=0.000) with the following NRTI mutations: A62V, S68G, S68N, Y115F and M184I. The 
frequency of these mutations in all sequences were 16%, 15%, 10%, 20% and 9% respectively. NNRTI 
mutations that correlated with K65R (p=0.000) were: V106M, Y181C, G190E and M230L, and were 
present at a frequency of 47%, 39%, 8% and 9% respectively. K65R also negatively correlated with the 
TAMs (D67N, K70R, L210W, T215F and T215Y), although they were found in combination in some 
sequences: D67N (5%), K70R (1.5%), L210W (0%), and T215F/Y (1%). 
 
Sequences from TDF treated patients were then separated according to their treatment history: those 
that only took TDF and those that took d4T prior to TDF.  
TDF-treated only: 147/475(31%) isolates harboured the K65R mutation. Eighteen mutations 
positively correlated with K65R, of these 5 were NRTI (A62V [22%], S68G [12%], S68N [16%],Y115F 
[21%] and M184I [11%]) and 8 were NNRTIs mutations. It also negatively correlated with TAMs 
(K70R, T215F/Y and K219Q) and 2 NNRTIs (A98S and P225H). 
D4T to TDF treated: 25/140 (18%) isolates harboured the K65R mutations. Significant (p=0.000) 
correlations were: A62V (20%), S68G (24%), S68N/K (12%) and Y115F (20%), as well as V106M 
(56%), Y181C (32%) and M230L (8%). Interestingly, the negative correlation with the TAMs was not 
seen in this group. Negative correlations were found between K65R and I135T (p=0.038) and K65R 











Table 1: subtype C sequences, correlation and association of K65R with other mutation from 
3 groups of TDF-treated 
  
 
2.3.6 K70E correlation with other NRTIs and NNRTIs 
K70E was investigated as an alternate pathway to TDF resistance. We found that 21/475 (4%) isolates 
harboured the K70E mutation. Only three of these isolates also harboured the K65R mutation; however 
this negative correlation with K65R was not statistically significant (p=0.09). K70E positively 
correlated with 5 NRTIs [D67N(p=0.000) V75I/S/T(p=0.009), M184V(p=0.001), E203K(p=0.014) and 
L228I/R(p=0.002)]. Correlation table in appendix A. K70E was found together with D67N in 52% of 
the sequences and with M184V in 81% of sequences. This is in contrast to the M184I variant that 
correlated with K65R, as shown above (Table 2). In addition, K70E correlated with 7 NNRTIs (V90I, 
     TDF-treated patients (overall)             TDF-treated patients only        TDF-treated patients  
             (d4T to TDF) 
Mutations P-value Percentage   Mutations P-value Percentage  Mutations P-value Percentage 
A62V 0.000** 16%   K46Q 0.007** 4%   E28V 0.027* 4% 
D67N 0.004** 5%   A62V 0.000** 22%   A62V 0.000** 20% 
S68G 0.000** 15%   S68G 0.000** 12%   S68G 0.000** 24% 
S68N 0.000** 10%   S68N 0.000** 16%   S68K 0.024* 4% 
K70R 0.004** 1.50%   K70R 0.002** 1%   S68N 0.018* 8% 
V75I 0.002** 5%   K70T 0.034* 1%   L74I 0.024* 4% 
L100I 0.004** 5%   N88S 0.003** 3%   V75I 0.001** 12% 
K101E 0.004** 15%   A98S 0.007** 3%   A98S 0.020* 16% 
K101Q 0.031* 5%   L100I 0.000** 7%   L100I 0.024* 12% 
K102R 0.000** 11%   K101E 0.000** 16%   K101R 0.024* 4% 
V106M 0.000** 47%   K102R 0.017* 7%   K102R 0.000** 20% 
V108I 0.035* 10%   V106M 0.000** 46%   K103H 0.024* 4% 
Y115F 0.000** 20%   Y115F 0.000** 21%   V106M 0.000** 56% 
I142V 0.019* 2%   E122P 0.034* 1%   L109M 0.024* 4% 
Q174K 0.049* 47%   Q174K 0.021*           54%   Y115F 0.000** 20% 
V179D 0.001** 15%   Y181C 0.000**        39%   I135T 0.038* 0% 
V179G 0.010* 1.50%   M184I 0.035* 11%   E138Q 0.024* 4% 
Y181C 0.000** 39%   G190A 0.017* 19%   K173L 0.024* 4% 
M184I 0.038* 9%   G190E 0.001** 6%   K173R 0.024* 4% 
G190E 0.000** 8%   G190S 0.005** 3%   Y181C 0.000** 32% 
G190S 0.006** 5%   T215F 0.006** 1%   Y188H 0.001** 8% 
L210W 0.036* 0%   T215Y 0.030* 0%   G190Q 0.024* 4% 
T215F 0.006** 0%   K219Q 0.014* 1%   R211D 0.025* 4% 
T215Y 0.027* 1%   P225H 0.006** 1%   R211K 0.009** 60% 
H221Y 0.003** 8%   M230L 0.000** 8%   F227A 0.025* 4% 
P225H 0.015* 1.50%   
   
  M230L 0.001** 8% 
M230L 0.000** 9%        
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A98G, K101A/D/R, K103S, V106M, G190A/E and K238T) and 3 novel mutations (E122P, T139K and 
G196R).  
 
2.3.7 TDF- treated pattern 
We manually investigated mutational patterns in those that were only TDF-treated. K65R in 
combination with Y115F was the most dominant pattern observed, followed by K65R with S68N and 
K65R with S68G. The combination of K65R and Y115F was seen in 15% (22/147) of the sequences, 
followed by S68G in 9% (13/147) of the sequences, while a novel combination with S68N occurred in 
14% (21/147) sequences. K65R+M184I was found in 10% (14/147) of the sequences The triple 
combination of K65R, S68G + Y115F mutations occurred in 3% (4/147) followed by K65R, 
S68N+Y115F; and K65R, L74V+Y115F mutations occurred in 2% (3/147) of the sequences. 
Interestingly, we also found mutations from the TAM II pathway in the TDF treated group (D67N, 
K70R and K219Q).  
 
Figure 2.6: Pie chart showing the TDF-treated mutational pattern. 
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In subtype C, K65R was found in 31% of TDF-treated and in 5% of d4T- treated sequences. This is in 
agreement with other studies that reported a high prevalence of K65R in subtype C (Skhosana et al., 
2015, Sunpath et al., 2012b). This was expected since TDF is known to select for K65R both in vivo 
and in vitro, while d4T selects for TAMs (Doualla-Bell et al., 2006, Kuritzkes et al., 2004, Sunpath et 
al., 2012b). However, K65R has also been found in d4T treated patients 5%, suggesting that K65R is 
also selected in d4T-treated isolates. Those that were TDF-treated also showed a negative correlation 
between the TAMs and K65R, which is in agreement with other studies that reported an antagonistic 
effect between K65R and TAMs. However, 2% of the TDF treated sequences also harbored mutations 
from the TAM 2 pathway. This was found in patients who took TDF with no prior history of d4T or 
AZT, which are the drugs known to select for TAMs.  
 
K46R was frequently selected in TDF-treated isolates and also positively correlated with K65R in 
subtype C. Also, K46Q was found only in sequences containing K65R. On the other hand, this was not 
the same with subtype B, therefore K46Q a may be associated with K65R in TDF-treated only in 
subtype C.  
 
K65R was found at a lower frequency (10%) in subtype B TDF-treated sequences. It is known that there 
is dissimilarity of the nucleotide sequence at codon K65, with nucleotide sequences AAA, AAG and 
AAG at position 64, 65 and 66 in subtype C and AAA-AGA nucleotide sequences in subtype B (Brenner 
and Coutsinos, 2009a, Garforth et al., 2014a).  
 
Y115F, which is known to be associated with K65R, was found in both C (6%) and B (2%) TDF treated 
isolates. The frequency was significantly higher (p<0.0001) in subtype C, suggesting that Y115F is 
more frequently selected under TDF pressure in subtype C. Initially, it was thought that Y115F was 
only selected in patients receiving ABC, however in a study by Skhosana et al, however 13.8% of TDF 
treated patients harboured Y115F and none of these patients were exposed in ABC (Miller et al., 2000, 
Skhosana et al., 2015).  Also, Y115F was reported to be selected after the development of K65R, and 
their combination is known to decrease TDF susceptibility (Stone et al., 2004, Das and Arnold, 2013).  
 
K70E was seen in 4% of TDF-treated sequences and has been previously reported to be selected in 
TDF-treated isolates (Skhosana et al., 2015); this was higher than in subtype B (1%). Furthermore, we 
also found negative correlation between K65R and K70E, which have been previously reported to have 
an antagonistic effect of K70E with K65R (Sluis-Cremer et al., 2007). It has been suggested that K70E 
is an alternative to the K65R pathway to TDF resistance (Kagan et al., 2007) While K65R and K70E 
have not previously been found together on the same viral genome, we did find that K65R and K70E 
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were detected in 3 sequences; however these were bulk sequences. K70E also negatively correlated 
with S68N and Y181C, which were positively correlated with K65R. Interestingly, K70E significantly 
correlate with one of the TAMs (D67N).  
 
Our data shows a significant correlation of K65R with the NNRTI mutations. It has been previously 
reported that K65R is highly associated with the use of EFV and NVP. NNRTI mutations were also 
strongly associated with TDF treatment: V106M, V179D, Y181C and G190A (p<0.0001). The 
association of K65R and Y181C and the pattern that include K65R, Y181C and G190 has also been 
previously reported in patient taking a combination therapy (Theys et al., 2009, von Wyl et al., 2008). 
Interestingly, K101E/Q and K103NS were associated with d4T treatment. This may be due to the 
positioning of the mutations within the NNRTI binding pocket; K101E and K103NS are located in the 




Other combinations with K65R that were found included S68G and L74V. These have been previously 
reported in subtype B sequences (Laura et al., 2008, Trotta et al., 2006). We also identified a 
combination of K65R with M184I. M184I is normally reported to change to M184V over time and its 
less fit than M184V (Hu and Kuritzkes, 2011). This is because HIV-1 is more prone to the change from 
G to A which results to M184I mutation. However, their enzymatic efficiency is less than that of M184V 
(Frost et al., 2000).  
Furthermore, we found a novel combination of K65R and S68N. The frequent combination of K65R 




Chapter 3 The interaction of K65R (and K70E) with other NRTI and NNRTI mutations 
in TDF exposed, using Bayesian network analysis and 3D homology modelling 
 
3.1 Introduction 
The high frequency of K65R in TDF-treated patients has been noted in several studies on subtype C 
(Hoffmann et al., 2013a, Skhosana et al., 2015, Van Zyl et al., 2013b).The increase of K65R in subtype 
C can be explained by the homopolymeric nature of nucleotide sequences at codon 64 and 65 (AAA-
AAG) in the RNA template (Coutsinos et al., 2009). Others have also reported that K65R can be 
selected by NNRTI mutations (Theys et al., 2009). Furthermore, K70E has also been shown to play a 
role in TDF resistance. In a study by Skhosana et al, a small number of TDF-treated developed K70E 
(Skhosana et al., 2015). This was also seen in our analysis as described in the previous chapter. 
Interestingly, K65R and K70E have been reported to be antagonistic and are rarely found on the same 
viral genome (Kagan et al., 2007, Skhosana et al., 2015). Both K65 and K70 residues are located within 
the β3-β4 loop found in the finger subdomain of HIV-1 RT (Sluis-Cremer et al., 2007). 
BNs have been successfully used to investigate the interactions of mutations that confer resistance to 
protease inhibitors (PIs), NRTIs and NNRTIs (Deforche et al., 2008, Theys et al., 2009). In particular, 
BN analysis has previously been used to identify positive associations of K65R with S68G, L100I and 
Y181C, as well as an antagonistic association with T215Y in HIV-1 subtype B (Theys et al., 2009).  
Homology modelling has also been used to investigate the  interaction of K65R with other resistance 
mutations e.g: K65R with M184V or Q151M and the negative association of K65R with L74V and 
most TAMs (Das et al., 2009). This is a computational technique, used to determine the three 
dimensional (3D) structure of proteins(Bishop et al., 2008). 3D protein structures provide valuable 
insights into the molecular basis of protein function (Schwede et al., 2003).  
In this chapter, we investigated the possibility of a Tenofovir-associated resistance pathway unique to 
subtype C. We address the following objectives set out in the thesis: 
a) To investigate the interaction of K65R with other NRTI and NNRTI mutations in subtype B and C 
using a Bayesian Network model. 





3.2.1 Bayesian network 
Bayesian network learning was done using the B-Course software programme available online 
(http:/www.b-course). Briefly, the dataset for BN analysis was prepared as a simple text file (tab 
delimited format) with the top row containing the name of the variables (mutations) and subsequent 
rows listing the cases (samples) to be analysed. The maximum size allowed for the dataset in B-Course 
is one megabyte; it is preferable to use a smaller dataset, since the larger the dataset, the longer it takes 
for the file to upload and be analysed. B-Course has 2 trail options: Dependency modelling and 
Classification. For our analysis, the Dependency model was used. The final network was provided as a 
picture (PNG). 
 
The strength of the arcs were taken from the final report provided for the network. The network arcs 
explain the dependency of the variables, and describe the effect of removing the arc on the probability 
of the model. Arcs with support of one billionth probability were considered robust (Table 2).The arc 
were coloured according to their estimated probability. The arc direction reflect the causal influence 
indicating the dependency of arcs (appendix B). Networks were constructed to investigate the direct 
interaction of mutations with K65R, and K70E in viral sequences obtained from TDF-experience 
patients. 
 
Table.2: The table below lists the different types of arcs that can be found in dependency models.  
 
 
The black arcs so 'strong' that removing any single one of 
them would cause the probability of the model to go down 
to less than one billionth of the probability of original model. 
 
 
The purple arcs are middle strong, so that removing any of 
them would results in a model with probability less than one 
millionth of that of the original model.  
 
 
Removing blue arcs from the model would decrease the 
probability of the model to less than one thousandth of the 
probability of the original model (exact ratio listed). 
 
 The red represents an antagonistic effect.  
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3.2.2 3D homology modelling 
3D homology modelling was done using SWISS-MODEL (https://swissmodel.expasy.org). Amino 
acids were uploaded to the SWISS-MODEL server. A template search was performed for models that 
best matched the query sequence with the highest percentage identity. The template was selected and 
the model was constructed on the SWISS-MODEL server. Structures were viewed and analysed in 
Chimera v1.8.1 (Petterson et al., 2004).  
 
3.3 Results 
3.3.1 Bayesian Network 
 
3.3.1.1 Subtype C TDF-resistance associated pathway 
The variables used in the data set for Bayesian network learning included mutations that were found to 
be associated with TDF-treatment and d4T-treatment. The dataset included all significant TDF-
resistance mutations. As seen in Figure15, the network showed a direct association between TDF and 
K65Rwith a high probability of 1billionth (strong bootstrap) and K70E, although this was only weakly 
supported (1 thousandth probability). Therefore, this suggested two separate TDF resistance pathways: 
one that included K65R and another that included K70E. The network also showed that there was no 









Figure 3.1: Bayesian Network learned from subtype C showing TDF-treated and d4T-treated mutations. 
Nodes represent mutations and exposure to treatment. Arc colour represents the probability support, removing 
any one of them would cause the probability of the model to go down by:  one billionth probability (Black), or  
one millionth probability (purple), or one thousandth probability (blue), or antagonistic influence (red).  
 
 
3.3.1.2 K65R pathway 
A separate network was investigated using only those mutations that correlated with K65R. This 
included a total of 29 variables. The BN analysis revealed a strongly supported association of K65R 
withY115F andY181C. The Y181C pathway was further associated with other NNRTI mutations: 
G190A/S, V108I and P225H. Lesser supported associations were with A62V, S68N, V106M, and 
M230L. The association with T215F indicated a strong antagonism towards K65R, which is in 






Figure 3.2: Bayesian Network expressing direct association between K65R and other mutations in TDF-
treated subtype C infected patients. The nodes represent all amino acid changes that were significantly 
associated with K65R Arc colour represents the probability support:  one billionth probability (Black), or  one 




3.3.1.3 K70E pathway 
The dataset included all mutations that correlated with K70E. The Bayesian Network showed a direct 
association of K65R with 1 NRTI (D67N) and 3 NNRTIs (98G, 101A 103S and 106M). The Network 
also revealed a strong association between K70E and D67N, while D67N showed an interaction with 






Figure 3.3: Bayesian Network expressing direct association between K70E and other mutations in TDF-
treated subtype C infected patients. The nodes represent all amino acid changes that were significantly 
associated with K70E in TDF-treated. Arc colour represents the probability support:  one billionth probability 





3.3.1.4 Subtype B TDF-resistance associated pathway 
 
A network was investigated using only mutations that correlated with K65R in subtype B. This included 
a total of 24 variables. Similar to Theys network, our subtype B network reveal the positive association 
of K65R with A62V, S68G, L100I, Y181C. It also showed an antagonistic association with 
T215Y.K65R pathway includes a direct positive association of 1 billion probability with 
Y181C.1millionth probability with A62V and 1 thousand probability with S68G and L100I. A62V and 






Figure 3.4: Bayesian Network expressing direct association between K65R and other mutations in TDF-
treated subtype B infected patients. The nodes represent all amino acid changes that were significantly 
associated with K65R. Arc colour represents the probability support:  one billionth probability (Black), or one 
millionth probability (purple), or one thousandth probability (blue), or an antagonistic influence (red). 
 
 
3.3.2 3D homology modelling 
 
Molecular modelling was used to visualize the positioning of the RT mutations that were found to be 
associated with TDF-resistance and their effect on the structure of RT. The positions of A62V, K65R 
D67N, S68G/N and K70E are shown on Figure 3.5. K65R, D67N, S68G/N and K70E are located in the 
β3- β4 loop within the finger sub-domain, while A62V, also located in the finger subdomain, and is 
found outside of theβ3- β4 loop. Interestingly, other mutations (Y115F and Y181C) that were also 




































Figure 3.5: RT structure showing the location of mutations that are associated with TDF-resistance. Finger 




3.3.2.1 K65R mutation 
 
The ball and stick representation shows differences between lysine (K65) and arginine (65R). The 
model shows a slight shift of 65R away from the wild type K65 residue (Figure 3.6A). This substitution 
may modify the positioning of this residue and affect the binding of the NRTI. S68G shifts away from 
the position of the wild type, and consequently moves away from codon 65. The distance between the 
wild type amino acids K65 and S68 (3Å) located within the β3 and β4 loop, is smaller than between the 
mutant residues 65R and 68N (4Å) (Figure 3.6B & C). Y115F (yellow) which is located in the α4 helix, 
loses the OH group present in the Tyrosine wild type residue (green) (Figure 3.6D) and therefore only 




















































Figure 3.6: Conformational difference among mutations that interact with K65R. (A) Structural difference 
between wild type and mutant at position 65 (purple- K65 and blue-R65). (B) Interaction of K65R with S68G, 












We also compared the positioning of M184I and M184V, since M184I correlated with K65R while 
M184V correlated with K70E.  M184 is located near the active site and usually mutates to 184V (purple) 
or 184I (yellow), which is more considered a transitional mutation. These mutations cause the residues 
to move distally away from wild type position, moving towards the active site (Figure 3.7 A & B), 


















Figure 3.7: Residue 184 interaction with the active site. Structural difference between wild type and mutant in 
position 184 (blue: M184: yellow: 184I, purple: 184V). (A) Structural change from M to V in position 184. (B) 




3.3.2.2 K70E mutation 
 
K70E is located on the same loop as K65R. Both 67N and 70E mutants move towards each other, while 
the wild type D67 and K70 are located distally away from each other (Figure 3.8B). The distance 































Figure 3.8: Conformational changes and interaction of double mutant K70E and D67N. Structural difference 



























Bayesian network learning identified 2 resistance mutations that are directly selected by TDF treatment 
in subtype C,  suggesting two separate TDF resistance pathways in this subtype C: one that includes 
K65R and another that includes K70E. However, since the frequency of  K70E in TDF treated patients 
is low, this pathway is rarely selected. Further analysis of the  K65R and it’s role in the pathway to TDF 
resistance identified positive associations with A62V, S68G/N, Y115F, Y181C and M230L, and a 
negative association with T215F. The network showed a strong asociation of K65R and S68N, and only 
a weak interaction with S68G, which is in contrast to a subtype B study that showed a strong interaction 
with S68G (Theys et al., 2009). A62V, S68G and Y115F have been previously reported to associate 
with K65R (Miller, 2003). A62V and S68G were reported to develop along with K65R, while Y115F 
was reported to be selected after the delelopment of K65R (Miller, 2003, Stone et al., 2004). The 
subtype C BN identified a strong association between K65R and Y115F. This was different from the 
subtype B BN of Theys et al which did not showed a direct interaction with Y115F (Theys et al., 2009). 
In addition, M230L was associated with M184I, which has also been previously reported; the effect of 
these two mutations together is still unknown (Deforche et al., 2008). The connection of K65R with the 
NNRTIs mutations in the BN suggests that there is cross resistance of K65R with the NNRTIs. It has 
been previously reported that reported the the presence of K65R and Y181C may contribute to the rapid 
failure of TDF and EFV/NVP treatment (Deforche et al., 2008). 
 
The alternate K70E pathway includes D67N, A98G, K101A, K103S and K106M. This suggest that 
K70E is associated with the TAM II pathway and the NNRTI mutations. These results are suprising 
since Sluis-Cremer et al, reported an antagonistic effect of K70E with the TAMs in subtype B. The 
network also revealed the association between D67N and M184V, which interacts with A62V and 
G190A.  
 
The Subtype B network showed an association beween K65R and A62V, S68G, L100I, Y181C and an 
antagonistic association with T215Y. This is similar to the network by They’s network that also showed 
an association between K65R and S68G, L100I, Y181C as well as an antagonistic effect on T215Y 
(Theys et al., 2009). Taken together, these  findings suggest that there are distinct differences in the 
pathways to TDF-resistance in subtype B and subtype C. 
 
The modelling showed that K65R and S68G/N are located in the β3 and β4 finger loop which suggests 
that they make contact with dNTPs when the finger fold towards the active site in the palm. The 
modelling also showed that residue 65R shifted away from making the contact with γ-phosphate, 




Phenylalanine at position 115 only includes the carbon rings and lack the OH, this may interrupt the 
hydrogen bonding between template and 3’pocket. Y181C loses the OH and other parts of the aromatic 
ring that are found in Y181 making it difficult to for the interaction with the NNRTIs. Therefore the 
interaction of K65R, Y115F and Y181C suggest that there is a high instability of hydrogen bonding 
leading to a disruption of NRTI binding.  
 
In addition, M184 is involved in the binding and positioning of the incoming dNTP and primer (Huang 
et al., 1998). Once mutated, β-branched of 184I/V block the active site and interfere with the binding 
of dNTP and primer.  
 
In conclusion, results suggest two pathways associated with TDF-resistance in subtype C. Both 
K65R and K70E are associated with NNRTI mutations, suggesting cross resistance between 
TDF and NNRTI mutations. K65R, Y115F and Y181C all undergo structural changes that 
disrupt the binding of NRTIs and possibly also the NNRTIs. 
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Chapter 4 Discussion and conclusion 
In South Africa, TDF is used in the current first line ARV regimen, as well as in the second-line regimen 
of the 2010 National guidelines (Organization, 2010). However its efficacy is limited by the 
development of K65R, a mutation associated with TDF resistance (Kagan et al., 2004). Prevalence 
reports of K65R in patients taking TDF in subtype C range between 23% and <65%, much higher than 
for subtype B (Hoffmann et al., 2013a, Sunpath et al., 2012b). This study investigated the mutational 
pathway and the role of K65R in the development of TDF resistance using a BN in both subtype B and 
C isolates. 
We found that K65R was the dominant TDF-resistance associated mutation observed and was selected 
in 31% of TDF-treated isolates in subtype C. This was in agreement with other subtype C studies that 
reported a K65R prevalence of 46% and 23% (Hoffmann et al., 2013a, Van Zyl et al., 2013b). 
Interestingly, K65R was also found in d4T treated isolates, suggesting that it is also selected by d4T-
treatment. This finding confirms a previous observation by Garcia-Lerma et al, who reported a K65R 
mediated-resistance pathway to d4T in nine recombinants using genotypic change analysis (García-
Lerma et al., 2003). However, K65R still remains rarely selected in d4T-treated isolates. In addition, 
this study compared the prevalence of K65R in subtype B versus C and found a lower prevalence of 
10% in subtype B.  
We then identified other mutations in both subtype B and C that were associated with TDF-treatment 
failure. We found that S68G was associated with K65R in subtype B while S68N was more common in 
subtype C isolates. S68N was also selected in d4T-treated sequences (0.4%); this was in the same 
sequences that developed K65R, and this may suggest that S68N is selected for during or after the 
development of K65R. The A62V and Y115F mutations occurred at a higher frequency in subtype C 
than in B. The TAMs were infrequently selected in TDF-treated isolates in both subtype B and C, 
although in subtype C, mutations involved in the TAMs II pathway were found in TDF-treated isolates. 
However, most of these were not found in the same sequences containing K65R. Furthermore, we also 
observed a high prevalence of NNRTI mutations in TDF-treated isolates. K70E was also found in 
limited TDF-treated isolates. Previous studies have also reported a low level of K70E in TDF-treated 
isolates (Delaugerre et al., 2008, Kagan et al., 2007). However, K65R still remained the main mutation 
that was associated with TDF exposure (Wensing et al., 2015).   
The BN was used to identify mutations in addition to K65R involved in the pathway to TDF- resistance. 
In our subtype C sequences, the presence of K65R correlated with 5 NRTIs: A62V, S68G/N, Y115F 
and M184I, and negatively correlated with the TAMs. This was confirmed using the BN, showing a 
highly selected association of K65R with A62V, S68N, Y115F, Y181C, and weaker association with 
V106M and M230l. However, the BN did not show any direct association with M184I; this association 
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was through M230L. The strongly supported association of K65R with S68N has not been previously 
reported and suggests a novel TDF resistance-associated mutation. This mutation is currently not listed 
in International AIDS Society (IAS) or Stanford HIV-1 Database. Also the strongly supported 
association of K65R with Y181C and weakly supported association with V106M suggest that there is 
cross-resistance with the NNRTIs. 
In subtype B, the TDF-resistance pathway, as seen in the BN, showed that only K65R was strongly 
supported to be associated with TDF exposure. While the K65R pathway showed a positive association 
with A62V, S68G, L100I and Y181C, it also showed a negative association with T215Y. This was 
expected as this has already been reported by Theys et al. However Theys’ network did not show the 
association of K65R and A62V. The main difference between the subtype B and C BN was the 
association of K65R and S68N in subtype C and the association with S68G in subtype B; this needs 
further investigation. S68N was selected in subtype C only, while S68G was selected in both subtypes. 
More striking was the strongly selected association of K65R with Y115F, which was seen only in the 
subtype C network. This mutation has previously been reported to occur in subtype C isolates, although 
this is the first time that the association with K65R has been made (Miller, 2003, Skhosana et al., 2015, 
Stone et al., 2004).  
Bayesian Network learning also identified a weakly supported direct association between TDF exposure 
and K70E. These results suggest that subtype C could have two different pathways to TDF resistance, 
one that involves K65R and the other that involves K70E. This is supported by the correlation results 
that showed a negative correlation between K65R and K70E, however this was not significant (p=0.92). 
As mentioned in chapter 2, K70E has been found in TDF treated isolates, albeit rarely. Furthermore, 
the K70E pathway included D67N and V106M, and weakly supported association with the NNRTI 
mutations A98G, K101A and K103S.  D67N is one of the mutations in TAM II pathway, which are 
known to have an antagonistic effect with K65R (White et al., 2006a). Therefore, it is possible that the 
selection of TAM II pathway in TDF-treated sequences is driven by this association. K70E positively 
correlated with M184V which is in line with a previous study that reported that K70E was always 
accompanied by M184V (Kagan et al., 2007). In the BN, there is no direct association between K70E 
and M184V, however the association of these is mediated by mutation D67N. 
We also investigated the structural changes that occur as a result of the K65R and associated mutations. 
A62V, K65R and S68G/N which are located in the finger region of RT, fold towards the active site in 
the palm to make contact with the incoming dNTPs (Sarafianos et al., 1999). More specifically, K65R 
and S68G/N are located in the β3 and β4 finger loop, while A62V is located outside of the β3 and β4 
finger loop, suggesting that A62V does not make any direct contact with the dNTP. Furthermore, Y115F 
and Y181C are located in the palm region and they form part of the binding pocket. Both mutations 
decrease binding of the NRTIs, because they make contact with the template backbone.  Y181C has 
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been reported to interact with NRTI resistance mutations and decrease binding of ATP as the excision 
substrate (Organization, 2010). 
 
The modelling also showed that K65R does not form a salt bridge with the γ-phosphate, therefore 
affecting the binding of the inhibitors. Lastly, the interaction of K65R, Y115F and Y181C suggest that 
there is a high instability of hydrogen bonding leading to the disruption of NRTI binding.  
 
In conclusion, our results suggest two distinct subtype C TDF-resistance pathways one involving K65R 
(which is the most common), and the other involving K70E. Both of these pathways are associated with 
NNRTI mutations (Y181C and V106M), suggesting some level of cross resistance. This is the first 
study to describe an association between K65R and S68N.The common pattern of K65R, Y115F and 
Y181C, which causes high level resistance to both TDF and EFV/NVP, raises concerns regarding the 
efficacy of the combination pill Truvada that is currently being used in the National ARV roll out. The 
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Appendix A: K70E correlation with NRTIs and NNRTIs mutations 
 
Table 1: K70E significant correlation table: NRTIs and NNRTIs Mutations that 
significantly correlated with K70E 
Mutations P-values correlation coefficient 
D67N 0.000** 0.315 
V75I 0.009** 0.12 
V75S 0.014* 0.112 
V75T 0.000** 0.214 
90I 0.031* 0.099 
A98G 0.019* 0.108 
K101A 0.000** 0.241 
K101D 0.002** 0.144 
K101R 0.044* 0.092 
K103S 0.015* 0.111 
V106M 0.008** 0.122 
E122P 0.002** 0.144 
139K 0015* 0.111 
M184V 0.001** 0.152 
G190A 0.006** 0.125 
G190E 0.037* 0.097 
196R 0.015* 0.111 
203K 0014* 0.113 
228I 0.002** 0.144 
228R 0.000** 0.196 











Appendix C: Bayesian Network causal arcs 
 
Table B: Different types of arcs that can be found in causal model 
Solid arc from A to B  
A has direct causal influence to B (direct meaning that causal 
influence is not mediated by any other variable that is included in 
the study)  
Dashed arc from A to B.  
There are two possibilities, but we do not know which holds. 
Either A is cause of B or there is a latent cause for both A and B.  
Dashed line without any 
arrow heads between A 
and B.  
There is a dependency but we do not know whether A causes B 
or if B causes A or if there is a latent cause of them both the 
dependency (confounding).  
 
 
 
